Biodexa Pharmaceuticals’ (BDRX) stock took a significant dive on Thursday despite positive updates from its ongoing MAGIC-1 study evaluating MTX110 in recurrent glioblastoma (rGBM). While the data suggests potential for a new treatment option, the stock’s reaction highlights investor uncertainty and market volatility.